Drug intelligence / Profile preview

UPT-211

Development stage: Preclinical
Lead developer: UPyTher
Administration: Intraperitoneal

Overview

UPT-211 is an investigational drug candidate developed by the Dutch biotech company UPyTher. It is designed for the treatment of peritoneal metastases, particularly those arising from colorectal cancer. UPT-211 is currently in preclinical development and represents a novel approach to targeting metastatic disease within the peritoneal cavity[3]. Specific details regarding its mechanism of action, molecular target, or modality have not been publicly disclosed as of June 2024.

Beyond the preview

Go deeper on UPT-211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UPT-211.

Explore the full profile